### Pre-Transplant Essential Data

**CIBMTR Use Only**

<table>
<thead>
<tr>
<th>Sequence Number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Received:</td>
</tr>
</tbody>
</table>

**Center Identification**

<table>
<thead>
<tr>
<th>CIBMTR Center Number: ___ ___ ___ ___</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBMT Code (CIC): ___ ___ ___ ___ ___ ___ ___ ___ ___ ___</td>
</tr>
</tbody>
</table>

**Recipient Identification**

<table>
<thead>
<tr>
<th>CIBMTR Research ID (CRID): ___ ___ ___ ___</th>
</tr>
</thead>
<tbody>
<tr>
<td>Event date: __ __ __ / __ __ / __ __</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>YYYY</th>
<th>MM</th>
<th>DD</th>
</tr>
</thead>
</table>

**OMB No:** 0915-0310  
**Expiration Date:** 03/31/2022

**Public Burden Statement:** The purpose of the data collection is to fulfill the legislative mandate to establish and maintain a standardized database of allogeneic marrow and cord blood transplants performed in the United States or using a donor from the United States. The data collected also meets the C.W. Bill Young Cell Transplantation Program requirements to provide relevant scientific information not containing individually identifiable information available to the public in the form of summaries and data sets. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0915-0310 and it is valid until 03/31/2022. This information collection is voluntary under The Stem Cell Therapeutic and Research Act of 2005, Public Law (Pub. L.) 109–129, as amended by the Stem Cell Therapeutic and Research Reauthorization Act of 2010, Public Law 111–264 (the Act) and the Stem Cell Therapeutic and Research Reauthorization Act of 2016, Public Law 114-104. Public reporting burden for this collection of information is estimated to average 0.70 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N136B, Rockville, Maryland, 20857 or paperwork@hrsa.gov.
Recipient Information

1. Date of birth: ___ ___ ___ ___ — ___ ___ — ___ ___
   YYYY MM DD

2. Sex
   □ Male
   □ Female

3. Ethnicity
   □ Hispanic or Latino
   □ Not Hispanic or Latino
   □ Not applicable (not a resident of the USA)
   □ Unknown

4. Race (check all that apply)
   □ White – Go to question 5
   □ Black or African American– Go to question 5
   □ Asian– Go to question 5
   □ American Indian or Alaska Native– Go to question 5
   □ Native Hawaiian or Other Pacific Islander– Go to question 5
   □ Not reported – Go to question 6
   □ Unknown– Go to question 6

5. Race detail (check all that apply)
   □ Eastern European
   □ Mediterranean
   □ Middle Eastern
   □ North Coast of Africa
   □ North American
   □ Northern European
   □ Western European
   □ White Caribbean
   □ White South or Central American
   □ Other White
   □ African
   □ African American
CIBMTR Center Number: ___ ___ ___ ___ ___ CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

- Black Caribbean
- Black South or Central American
- Other Black
- Alaskan Native or Aleut
- North American Indian
- American Indian, South or Central America
- Caribbean Indian
- South Asian
- Filipino (Philipino)
- Japanese
- Korean
- Chinese
- Vietnamese
- Other Southeast Asian
- Guamanian
- Hawaiian
- Samoan
- Other Pacific Islander
- Unknown

6. Country of primary residence

- Afghanistan
- Aland Islands
- Albania
- Algeria
- American Samoa
- Andorra
- Angola
- Anguilla
- Antarctica
- Antigua and Barbuda
- Argentina
- Armenia
- Aruba
- Australia
- Austria
- Ghana
- Gibraltar
- Greece
- Greenland
- Grenada
- Guadeloupe
- Guam
- Guatemala
- Guernsey
- Guinea
- Guinea-Bissau
- Guyana
- Haiti
- Heard Island and McDonald Islands
- Holy See
- Palau
- Palestine, State of
- Panama
- Papua New Guinea
- Paraguay
- Peru
- Philippines
- Pitcairn Islands
- Poland
- Portugal
- Puerto Rico
- Qatar
- Reunion
- Romania
- Russia

Copyright © 2021 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved.
- Azerbaijan
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belarus
- Belgium
- Belize
- Benin
- Bermuda
- Bhutan
- Bolivia
- Bonaire, Sint Eustatius and Saba
- Bosnia and Herzegovina
- Botswana
- Bouvet Island
- Brazil - Go to question 7
- British Indian Ocean Territory
- British Virgin Islands
- Brunei Darussalam
- Bulgaria
- Burkina Faso
- Burundi
- Cambodia
- Cameroon
- Canada - Go to question 8
- Cape Verde
- Cayman Islands
- Central African Republic
- Chad
- Chile
- China
- Christmas Island
- Cocos (Keeling) Islands
- Colombia
- Honduras
- Hong Kong
- Hungary
- Iceland
- India
- Indonesia
- Iran
- Iraq
- Ireland
- Isle of Man
- Israel
- Italy
- Jamaica
- Japan
- Jersey
- Jordan
- Kazakhstan
- Kenya
- Kiribati
- Kuwait
- Kyrgyzstan
- Laos
- Latvia
- Lebanon
- Lesotho
- Liberia
- Libya
- Liechtenstein
- Lithuania
- Luxembourg
- Macau
- Macedonia
- Madagascar
- Malawi
- Malaysia
- Maldives
- Rwanda
- Saint Barthelemy
- Saint Helena
- Saint Kitts and Nevis
- Saint Lucia
- Saint Martin, French
- Saint Pierre and Miquelon
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- Sao Tome and Principe
- Saudi Arabia
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Singapore
- Sint Maarten, Dutch
- Slovak Republic
- Slovenia
- Solomon Islands
- Somalia
- South Africa
- South Georgia and the South Sandwich Islands
- South Korea
- South Sudan
- Spain
- Sri Lanka
- Sudan
- Suriname
- Svalbard and Jan Mayen
- Swaziland
- Sweden
- Switzerland
- Syria
7. State of residence of recipient *(for residents of Brazil)*

- Acre
- Alagoas
- Amapá
- Amazonas
- Bahia
- Ceará
- Distrito Federal
- Espírito Santo
- Goiás
- Maranhão
- Mato Grosso
- Mato Grosso do Sul
- Minas Gerais
- Pará
- Paraíba
- Paraná
- Pernambuco
- Piauí
- Rio de Janeiro
- Rio Grande do Norte
- Rio Grande do Sul
- Rondônia
- Roraima
- Santa Catarina
- São Paulo
- Sergipe
- Tocantins

8. Province or territory of residence of recipient *(for residents of Canada)*

- Alberta
- British Columbia
- Manitoba
- New Brunswick
- Newfoundland and Labrador
- Nova Scotia
- Ontario
- Prince Edward Island
- Quebec
- Saskatchewan

9. State of residence of recipient *(for residents of USA)*

- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
CIBMTR Center Number: ___ ___ ___ ___ ___ CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

☐ Florida ☐ Montana ☐ Texas
☐ Georgia ☐ Nebraska ☐ Utah
☐ Hawaii ☐ Nevada ☐ Vermont
☐ Idaho ☐ New Hampshire ☐ Virginia
☐ Illinois ☐ New Jersey ☐ Washington
☐ Indiana ☐ New Mexico ☐ West Virginia
☐ Iowa ☐ New York ☐ Wisconsin
☐ Kansas ☐ North Carolina ☐ Wyoming

10. NMDP Recipient ID (RID): __ __ __ __ __ __ __

11. Zip or postal code for place of recipient’s residence (USA and Canada recipients only): ______ ___ ___ ___ ___

12. Specify blood type (of recipient) (For allogeneic HCTs only)
   □ A
   □ B
   □ AB
   □ O

13. Specify Rh factor (of recipient) (For allogeneic HCTs only)
   □ Positive
   □ Negative

14. Has the recipient signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR? (For allogeneic HCTs only)
   □ Yes (recipient consented) – Go to question 15
   □ No (recipient declined) - Go to question 18
   □ Not approached - Go to question 18
   □ Not applicable (center not participating) - Go to question 18

15. Date form was signed: ___ ___ ___ ___ — ___ ___ — ___ ___
    YYYY  MM  DD

16. Did the recipient submit a research sample to the NMDP/CIBMTR repository? (Related donors only)
   □ Yes – Go to question 17

Copyright © 2021 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved.
CIBMTR Center Number: ___ ___ ___ ___ ___ CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

17. Research sample recipient ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

18. Is the recipient participating in a clinical trial? (clinical trial sponsors that use CIBMTR forms to capture outcomes data)
   - Yes - Go to question 19
   - No – Go to question 24

19. Study Sponsor
   - BMT CTN – Go to question 21
   - RCI BMT – Go to question 21
   - PIDTC – Go to question 21
   - USIDNET – Go to question 22
   - COG – Go to question 22
   - Other sponsor – Go to question 20

20. Specify other sponsor: ________________________________ - Go to question 22

21. Study ID Number: __________________________

22. Subject ID: __________________________

23. Specify the ClinicalTrials.gov identification number: NCT ________

Copy questions 19-23 to report participation in more than one study.

Hematopoietic Cellular Transplant (HCT) and Cellular Therapy

24. Is a subsequent HCT planned as part of the overall treatment protocol? (not as a reaction to post-HCT disease assessment) (For autologous HCTs only)
   - Yes – Go to question 25
   - No – Go to question 26

25. Specify subsequent HCT planned
   - Autologous
   - Allogeneic

26. Has the recipient ever had a prior HCT?
   - Yes – Go to question 27
   - No – Go to question 38
27. Specify the number of prior HCTs: ___ ___

28. Were all prior HCTs reported to the CIBMTR?
   □ Yes – Go to question 33
   □ No – Go to question 29
   □ Unknown – Go to question 33

Copy and complete questions 29-32 to report all prior HCTs that have not yet been reported to the CIBMTR

29. Date of the prior HCT: ___ ___ ___ ___ — ___ ___ — ___ ___ □ Date estimated
    YYYY MM DD

30. Was the prior HCT performed at a different institution?
   □ Yes – Go to question 31
   □ No – Go to question 32

Specify the institution that performed the last HCT

31. Name: _______________________________________________________________
    City:__________________________________________________________________
    State: _________________________________________________________________
    Country: _______________________________________________________________

32. What was the HPC source for the prior HCT? (check all that apply)
   □ Autologous
   □ Allogeneic, unrelated
   □ Allogeneic, related

33. Reason for current HCT
   □ Graft failure / insufficient hematopoietic recovery – Go to question 34
   □ Persistent primary disease – Go to question 38
   □ Recurrent primary disease – Go to question 35
   □ Planned subsequent HCT, per protocol – Go to question 38
   □ New malignancy (including PTLD and EBV lymphoma) – Go to question 36
   □ Insufficient chimerism – Go to question 38
   □ Other – Go to question 37

34. Date of graft failure / rejection: ___ ___ ___ ___ — ___ ___ — ___ ___ – Go to question 38
35. Date of relapse: ____ ____ ___ — ____ — ____ — Go to question 38

36. Date of secondary malignancy: ____ ____ ___ — ____ — ____ — Go to question 38

37. Specify other reason: __________________________ - Go to question 38

38. Has the recipient ever had a prior cellular therapy? (do not include DLIs)
   □ Yes – Go to question 39
   □ No – Go to question 44
   □ Unknown– Go to question 44

39. Were all prior cellular therapies reported to the CIBMTR?
   □ Yes – Go to question 44
   □ No – Go to question 40
   □ Unknown– Go to question 44

   Copy and complete questions 40-43 to report all prior cellular therapies that have not yet been reported to the CIBMTR

40. Date of the prior cellular therapy: ____ ____ ___ — ____ — ____ —

41. Was the cellular therapy performed at a different institution?
   □ Yes – Go to question 42
   □ No – Go to question 43

42. Name: ___________________________________________________________________
    City: _____________________________________________________________________
    State: ___________________________________________________________________
    Country: __________________________________________________________________

43. Specify the source(s) for the prior cellular therapy (check all that apply)
   □ Autologous
   □ Allogeneic, unrelated
   □ Allogeneic, related
Donor Information

44. Multiple donors?
   □ Yes – Go to question 45
   □ No - Go to question 46

45. Specify number of donors: ___ ___

To report more than one donor, copy questions 46-82 and complete for each donor.

46. Specify donor
   □ Autologous
   □ Allogeneic, related
   □ Allogeneic, unrelated

47. Specify product type (check all that apply)
   □ Bone marrow
   □ PBSC
   □ Single cord blood unit
   □ Other product– Go to question 48

48. Specify other product: _______________________________________

49. Is the product genetically modified? If autologous, go to question 77. If allogeneic related, go to question 50. If allogeneic unrelated, go to question 54.
   □ Yes
   □ No

50. Specify the related donor type
   □ Syngeneic (monozygotic twin) – Go to question 55
   □ HLA-identical sibling (may include non-monozygotic twin) – Go to question 55
   □ HLA-matched other relative (does NOT include a haplo-identical donor) - Go to question 51
   □ HLA-mismatched relative– Go to question 51

51. Specify the biological relationship of the donor to the recipient
   □ Mother
   □ Father
   □ Child
   □ Sibling
☐ Fraternal twin
☐ Maternal aunt
☐ Maternal uncle
☐ Maternal cousin
☐ Paternal aunt
☐ Paternal uncle
☐ Paternal cousin
☐ Grandparent
☐ Grandchild
☐ Other biological relative – Go to question 52

52. Specify other biological relative: _________________________ – Go to question 53

53. Degree of mismatch (related donors only)
☐ HLA-mismatched 1 allele – Go to question 55
☐ HLA-mismatched >2 alleles (does include haplo-identical donor) – Go to question 55

54. Specify unrelated donor type
☐ HLA matched unrelated
☐ HLA mismatched unrelated

55. Did NMDP / Be the Match facilitate the procurement, collection, or transportation of the product?
☐ Yes
☐ No

56. Was this donor used for any prior HCTs? (for this recipient)
☐ Yes
☐ No

57. NMDP cord blood unit ID: ____________ – Go to question 72

58. Registry donor ID: (not applicable for related donors)
__________________________ - Go to question 63

59. Non-NMDP cord blood unit ID: (include related and autologous CBUs)
__________________________ - Go to question 61
60. Global Registration Identifier for Donors (GRID):

    __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __ __

    *NMDP donor, go to question 72*

    *Non-NMDP unrelated donor, go to question 63*

61. Is the CBU ID also the ISBT DIN number?

   □ Yes – **Go to question 63**
   □ No – **Go to question 62**
   □ Unknown- **Go to question 63**

62. Specify the ISBT DIN number: __________________________________________

63. Registry or UCB Bank ID: ___ ___ ___ ___ - If ‘Other registry’ go to 64, otherwise go to question 65

64. Specify other Registry or UCB Bank: _______________________________ - **Go to question 65**

65. Donor date of birth

   □ Known – **Go to question 66**
   □ Unknown – **Go to question 67**

66. Donor date of birth: ___________ — __________ — __________ - **Go to question 69**

   YYYY MM DD

67. Donor age

   □ Known – **Go to question 68**
   □ Unknown – **Go to question 69**

68. Donor age: ____ □ Months *(use only if less than 1 year old)*

69. Donor sex

   □ Male
   □ Female

70. Specify blood type *(donor) (non-NMDP allogeneic donors only)*

   □ A
   □ B
   □ AB
   □ O
71. Specify Rh factor *(donor)* *(non-NMDP allogeneic donors only)*
   - [ ] Positive
   - [ ] Negative

72. Donor CMV-antibodies *(IgG or Total)* *(Allogeneic HCTs only)*
   - [ ] Reactive
   - [ ] Non-reactive
   - [ ] Indeterminate
   - [ ] Not done
   - [ ] Not applicable *(cord blood unit)*

73. Has the donor signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR? *(Related donors only)*
   - [ ] Yes *(donor consented) – Go to question 74*
   - [ ] No *(donor declined) - Go to question 77*
   - [ ] Not approached - *Go to question 77*
   - [ ] Not applicable *(center not participating) - Go to question 77*

74. Date form was signed: ____ ____ ____ ____ — ____ ____ — ____ ____
    YYYY  MM  DD

75. Did the donor submit a research sample to the NMDP/CIBMTR repository? *(Related donors only)*
   - [ ] Yes – *Go to question 76*
   - [ ] No – *Go to question 77*

76. Research sample donor ID: ____ ____ ____ ____ ____ ____ ____ ____ ____

77. Specify number of products infused from this donor: ____

78. Specify the number of these products intended to achieve hematopoietic engraftment: ____

**Questions 79-80 are for autologous HCT recipients only.**

79. What agents were used to mobilize the autologous recipient for this HCT? *(check all that apply)*
   - [ ] G-CSF *(filgrastim, Neupogen)*
   - [ ] Pegylated G-CSF *(pegfilgrastim, Neulasta)*
   - [ ] Plerixafor *(Mozobil)*
   - [ ] Combined with chemotherapy
80. Specify other agent: ___________________

81. Name of product: (gene therapy recipients)
   □ Other name

   82. Specify other name: ____________________

To report more than one donor, copy questions 46-82 and complete for each donor.

**Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning)**

83. What scale was used to determine the recipient’s functional status?
   □ Karnofsky (recipient age ≥ 16 years) – Go to question 84
   □ Lansky (recipient age ≥ 1 year and < 16 years) – Go to question 85

**Performance score prior to the preparative regimen:**

84. Karnofsky Scale (recipient age ≥ 16 years)
   □ 100 Normal; no complaints; no evidence of disease - Go to question 86
   □ 90 Able to carry on normal activity - Go to question 86
   □ 80 Normal activity with effort - Go to question 86
   □ 70 Cares for self; unable to carry on normal activity or to do active work - Go to question 86
   □ 60 Requires occasional assistance but is able to care for most needs - Go to question 86
   □ 50 Requires considerable assistance and frequent medical care - Go to question 86
   □ 40 Disabled; requires special care and assistance - Go to question 86
   □ 30 Severely disabled; hospitalization indicated, although death not imminent - Go to question 86
   □ 20 Very sick; hospitalization necessary - Go to question 86
   □ 10 Moribund; fatal process progressing rapidly - Go to question 86

85. Lansky Scale (recipient age ≥ 1 year and < 16 years)
   □ 100 Fully active
   □ 90 Minor restriction in physically strenuous play
   □ 80 Restricted in strenuous play, tires more easily, otherwise active
   □ 70 Both greater restrictions of, and less time spent in, active play
   □ 60 Ambulatory up to 50% of time, limited active play with assistance / supervision
   □ 50 Considerable assistance required for any active play; fully able to engage in quiet play
40. Able to initiate quiet activities
30. Needs considerable assistance for quiet activity
20. Limited to very passive activity initiated by others (e.g., TV)
10. Completely disabled, not even passive play

86. Recipient CMV-antibodies (IgG or Total)
   - Reactive
   - Non-reactive
   - Indeterminate
   - Not done

Comorbid Conditions

87. Has the patient been infected with COVID-19 (SARS-CoV-2) based on a positive test result at any time prior to the start of the preparative regimen / infusion?
   - Yes – Go to question 88
   - No – Go to question 90

88. Did the patient require hospitalization for management of COVID-19 (SARS-CoV-2) infection?
   - Yes – Go to question 89
   - No – Go to question 90

89. Was mechanical ventilation used for COVID-19 (SARS-CoV-2) infection?
   - Yes
   - No

90. Was a vaccine for COVID-19 (SARS-CoV-2) received?
   - Yes – Go to question 91
   - No – Go to question 95
   - Unknown – Go to question 95

Copy and complete questions 91-94 to report all vaccine doses received.

91. Specify vaccine brand
   - AstraZeneca – Go to question 93
   - Johnson & Johnson’s / Janssen – Go to question 93
   - Moderna – Go to question 93
   - Novavax – Go to question 93
   - Pfizer-BioNTech – Go to question 93
92. Specify other type: __________

93. Select dose(s) received
   - One dose (without planned second dose)
   - First dose (with planned second dose)
   - Second dose
   - Third dose
   - Booster dose

94. Date received: ___ ___ ___ ___ — ___ ___ — ___ ___  □ Date estimated

   YYYY  MM  DD

95. Is there a history of mechanical ventilation (excluding COVID-19 (SARS-CoV-2))?  
   - Yes
   - No

96. Is there a history of invasive fungal infection?  
   - Yes
   - No

97. Glomerular filtration rate (GFR) before start of preparative regimen (pediatric only)  
   - Known- Go to question 98
   - Unknown- Go to question 99

98. Glomerular filtration rate (GFR): __ __ __ mL/min/1.73²

99. Does the recipient have known complex congenital heart disease? (corrected or uncorrected) (excluding simple ASD, VSD, or PDA repair) (pediatric only)  
   - Yes
   - No

100. Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI)? (Source: Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863.)  
    - Yes- Go to question 101
    - No- Go to question 107

101. Specify co-existing diseases or organ impairment (check all that apply)
Arrhythmia - Any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebral thrombosis, embolism, or hemorrhage

Diabetes - Requiring treatment with insulin or oral hypoglycemic drugs in the last 4 weeks but not diet alone

Heart valve disease - At least a moderate to severe degree of valve stenosis or insufficiency as determined by Echo; prosthetic mitral or aortic valve; or symptomatic mitral valve prolapse

Hepatic, mild - Bilirubin > upper limit of normal to 1.5 x upper limit of normal, or AST/ALT > upper limit of normal to 2.5 x upper limit of normal at the time of transplant OR any history of hepatitis B or hepatitis C infection

Hepatic, moderate/severe - Liver cirrhosis, bilirubin > 1.5 x upper limit of normal, or AST/ALT > 2.5 x upper limit of normal

Infection - Includes a documented infection, fever of unknown origin, or pulmonary nodules suspicious for fungal pneumonia or a positive PPD test requiring prophylaxis against tuberculosis. Patients must have started antimicrobial treatment before Day 0 with continuation of antimicrobial treatment after Day 0

Inflammatory bowel disease - Any history of Crohn’s disease or ulcerative colitis requiring treatment

Obesity - Patients older than 18 years with a body mass index (BMI) > 35 kg/m2 prior to the start of conditioning or a BMI of the 95th percentile of higher for patients aged 18 years or younger

Peptic ulcer - Any history of peptic (gastric or duodenal) ulcer confirmed by endoscopy or radiologic diagnosis requiring treatment

Psychiatric disturbance - Presence of any mood (e.g., depression), anxiety, or other psychiatric disorder (e.g. bipolar disorder or schizophrenia) requiring continuous treatment in the last 4 weeks

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 of 66-80% or dyspnea on slight activity attributed to pulmonary disease at transplant

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 of ≤ 65% or dyspnea at rest attributed to pulmonary disease or the need for intermittent or continuous oxygen during the 4 weeks prior to transplant

Renal, moderate / severe - Serum creatinine > 2 mg/dL or > 177 μmol/L; on dialysis during the 4 weeks prior to transplant; OR prior renal transplantation - go to question 102

Rheumatologic - Any history of a rheumatologic disease (e.g., systemic lupus erythematosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica, etc.) requiring treatment. (Do NOT include degenerative joint disease, osteoarthritis)

Prior malignancy - Treated at any time point in the patient’s past history, other than the primary disease for which this infusion is being performed - go to question 103

102. Was the recipient on dialysis immediately prior to start of preparative regimen?
103. Specify prior malignancy (check all that apply)
- Yes
- No
- Unknown

 Specify prior malignancy:
- Breast cancer
- Central nervous system (CNS) malignancy (e.g., glioblastoma, astrocytoma)
- Gastrointestinal malignancy (e.g., colon, rectum, stomach, pancreas, intestine, esophageal)
- Genitourinary malignancy (e.g., kidney, bladder, ovary, testicle, genitalia, uterus, cervix, prostate)
- Leukemia (includes acute or chronic leukemia)
- Lung cancer
- Lymphoma (includes Hodgkin & non-Hodgkin lymphoma)
- MDS / MPN
- Melanoma
- Multiple myeloma / plasma cell disorder (PCD)
- Oropharyngeal cancer (e.g., tongue, buccal mucosa)
- Sarcoma
- Thyroid cancer
- Other skin malignancy (basal cell, squamous) - go to question 104
- Other hematologic malignancy - go to question 105
- Other solid tumor - go to question 106

104. Specify other skin malignancy: (prior) ____________________________

105. Specify other hematologic malignancy: (prior) ____________________________

106. Specify other solid tumor: (prior) ____________________________

Use results within 4 weeks prior to the start of the preparative regimen, report results from the test performed closest to the start date. Biomarkers according to the augmented HCT comorbidity index. (Source: Biol Blood Marrow Transplant. 2015 Aug; 21(8): 1418–1424)

107. Serum ferritin (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
- Known – Go to question 108
- Unknown – Go to question 111

108. ___ ___ ___ ___ ng/mL (μg/L)
109. Date sample collected: ___ ___ ___ ___ — ___ ___ — ___ ___  
   YYYY MM DD

110. Upper limit of normal for your institution: ___ ___ ___ ___

111. Serum albumin (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
   □ Known – Go to question 112
   □ Unknown – Go to question 114

112. ___ ___ • ___  □ g/dL  
       □ g/L

113. Date sample collected: ___ ___ ___ ___ — ___ ___ — ___ ___  
   YYYY MM DD

114. Platelets (within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)
   □ Known – Go to question 115
   □ Unknown – Go to question 117

115. ___ ___ ___ ___ ___ ___  □ x 10^9/L (x 10^9/mm^3)  
       □ x 10^6/L

116. Were platelets transfused ≤ 7 days before date of test?  
   □ Yes  
   □ No  
   □ Unknown

117. Did the recipient have a prior solid organ transplant?  
   □ Yes- Go to question 118  
   □ No- Go to question 121

118. Specify organ:
   □ Bowel
   □ Heart
   □ Kidney(s)
   □ Liver
   □ Lung(s)
   □ Pancreas
   □ Other organ- Go to question 119
119. Specify other organ: ________________________________

120. Year of prior solid organ transplant: ___ ___ ___ ___  
    YYYY

*Copy and complete questions 118-120 for each prior solid organ transplant*

### Pre-HCT Preparative Regimen (Conditioning)

121. Height at initiation of pre-HCT preparative regimen: ___ ___  
    □ inches  
    □ centimeters

122. Actual weight at initiation of pre-HCT preparative regimen: ___ ___ . ___  
    □ pounds  
    □ kilograms

123. Was a pre-HCT preparative regimen prescribed?  
    □ Yes – *Go to question 124*  
    □ No – *Go to question 132*

124. Classify the recipient’s prescribed preparative regimen (*Allogeneic HCTs only*)  
    □ Myeloablative  
    □ Non-myeloablative (NST)  
    □ Reduced intensity (RIC)

125. Was irradiation planned as part of the pre-HCT preparative regimen?  
    □ Yes – *Go to question 126*  
    □ No – *Go to question 131*

126. What was the prescribed radiation field?  
    □ Total body – *Go to question 127*  
    □ Total body by intensity-modulated radiation therapy (IMRT) – *Go to question 127*  
    □ Total lymphoid or nodal regions – *Go to question 127*  
    □ Thoracoabdominal region – *Go to question 127*

127. Total prescribed dose: (*dose per fraction x total number of fractions*) ___ ___ ___ ___ . ___  
    □ Gy  
    □ cGy

128. Date started: ___ ___ ___ ___ — ___ ___ — ___ ___  
    YYYY MM DD
129. Was the radiation fractionated?
   - Yes – **Go to question 130**
   - No – **Go to question 131**

130. Total number of fractions: ____

**Indicate the total prescribed cumulative dose for the preparative regimen**

131. Drug *(drop down list)*
   - Bendamustine
   - Busulfan
   - Carboplatin
   - Carmustine (BCNU)
   - CCNU (Lomustine)
   - Clofarabine (Clolar)
   - Cyclophosphamide (Cytoxan)
   - Cytarabine (Ara-C)
   - Etoposide (VP-16, VePesid)
   - Fludarabine
   - Gemcitabine
   - Ibritumomab tiuxetan (Zevalin)
   - Ifosfamide
   - Melphalan (L-Pam)
   - Methylprednisolone (Solu-Medrol)
   - Pentostatin
   - Propylene glycol-free melphalan (Evomela)
   - Rituximab (Rituxan)
   - Thiopeta
   - Tositumomab (Bexxar)
   - Treosulfan
   - Other drug -**go to question 132**

132. Specify other drug: ___________

133. Total prescribed dose: ___ ___ ___ ___.____  □ mg/m²
    □ mg/kg
    □ AUC (mg x h/L)
134. Date started: _____ _____ — _____ — _____
       YYYY   MM   DD

135. Specify administration (busulfan only)
   □ Oral
   □ IV
   □ Both

Copy and complete question 131-135 to report each drug given for the preparative regimen

Additional Drugs Given in the Peri-Transplant Period

136. ALG, ALS, ATG, ATS
   □ Yes – Go to question 137
   □ No – Go to question 140

137. Total prescribed dose: _____ _____ _____ _____ mg/kg

138. Specify source
   □ ATGAM (horse) – Go to question 140
   □ ATG – Fresenius (rabbit) – Go to question 140
   □ Thymoglobulin (rabbit) – Go to question 140
   □ Other – Go to question 139

139. Specify other source: _____________________

140. Alemtuzumab (Campath)
   □ Yes – Go to question 141
   □ No – Go to question 142

141. Total prescribed dose: _____ _____  _____  .  _____ □ mg/m2

                                □ mg/kg
                                □ mg

142. Defibrotide
   □ Yes
143. KGF

☐ Yes
☐ No

144. Ursodiol

☐ Yes
☐ No

GVHD Prophylaxis

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 148.

145. Was GVHD prophylaxis planned?

☐ Yes - Go to question 146
☐ No - Go to question 148

146. Specify drugs / intervention (check all that apply)

☐ Abatacept
☐ Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
☐ Blinded randomized trial
☐ Bortezomib
☐ CD34 enriched (CD34+ selection)
☐ Corticosteroids (systemic)
☐ Cyclophosphamide (Cytoxan)
☐ Cyclosporine (CSA, Neoral, Sandimmune)
☐ Extra-corporeal photopheresis (ECP)
☐ Ex-vivo T-cell depletion
☐ Filgotinib
☐ Maraviroc
☐ Methotrexate (MTX) (Amethopterin)
☐ Mycophenolate mofetil (MMF) (CellCept)
☐ Ruxolotinib
☐ Sirolimus (Rapamycin, Rapamune)
☐ Tacrolimus (FK 506)
Specify other agent: ______________ (do not report ATG, campath)

Post-HCT Disease Therapy Planned as of Day 0

148. Is additional post-HCT therapy planned?
   □ Yes - Go to question 149
   □ No - Go to First Name

Questions 149–150 are optional for non-U.S. centers

149. Specify post-HCT therapy planned (check all that apply)
   □ Azacytidine (Vidaza)
   □ Blinatumomab
   □ Bortezomib (Velcade)
   □ Bosutinib
   □ Brentuximab
   □ Carfilzomib
   □ Cellular therapy (e.g. DCI, DLI)
   □ Crenolanib
   □ Daratumumab
   □ Dasatinib
   □ Decitabine
   □ Elotuzumab
   □ Enasidenib
   □ Gilteritinib
   □ Ibrutinib
   □ Imatinib mesylate (Gleevec, Glivec)
   □ Intrathecal therapy (chemotherapy)
   □ Ivosidenib
   □ Ixazomib
   □ Lenalidomide (Revlimid)
   □ Lestaurtinib
   □ Local radiotherapy
   □ Midostaurin
Nilotinib
Obinutuzumab
Pacritinib
Ponatinib
Quizartinib
Rituximab (Rituxan, MabThera)
Sorafenib
Sunitinib
Thalidomide (Thalomid)
Other therapy- Go to question 150
Unknown

150. Specify other therapy: ____________________________

Prior Exposure: Potential Study Eligibility

Selecting any option(s) below may generate an additional supplemental form.

151. Specify if the recipient received any of the following (at any time prior to HCT / infusion) (check all that apply)
   - Blinatumomab (Blincyto)
   - Gemtuzumab ozogamicin (Mylotarg)
   - Inotuzumab ozogamicin (Besponsa)
   - Adienne Tepadina®
   - Mogamulizumab (Poteligeo)
   - None of the above

First Name: ____________________________________________________________________________
Last Name: ____________________________________________________________________________
E-mail address: __________________________________________________________________________
Date: ___ ___ ___ ___ — ___ ___ — ___ ___
      YYYY  MM  DD